Jefferies Group Reaffirms Hold Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reiterated by research analysts at Jefferies Group in a report released on Wednesday. They currently have a GBX 4,500 ($75.23) price target on the stock. Jefferies Group’s price target suggests a potential upside of 6.17% from the company’s current price.
AZN has been the subject of a number of other recent research reports. Analysts at Credit Suisse reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, August 14th. They now have a GBX 4,800 ($80.24) price target on the stock. Separately, analysts at Societe Generale reiterated a “sell” rating on shares of AstraZeneca plc in a research note on Wednesday, August 13th. They now have a GBX 3,700 ($61.85) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “underweight” rating on shares of AstraZeneca plc in a research note on Friday, August 8th. They now have a GBX 3,700 ($61.85) price target on the stock. Six equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of GBX 4,055.48 ($67.79).
AstraZeneca plc (LON:AZN) opened at 4275.50 on Wednesday. AstraZeneca plc has a one year low of GBX 3086.50 and a one year high of GBX 5750.00. The stock has a 50-day moving average of GBX 4313.37 and a 200-day moving average of GBX 4203.60. The company’s market cap is £54.000 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.